Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $16.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 337.16% from the stock’s current price.

A number of other brokerages also recently issued reports on ESPR. Needham & Company LLC lowered their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Esperion Therapeutics Stock Up 12.6 %

NASDAQ:ESPR opened at $3.66 on Tuesday. The stock’s 50-day simple moving average is $2.22 and its 200 day simple moving average is $2.18. The firm has a market capitalization of $721.15 million, a PE ratio of -5.72 and a beta of 1.01. Esperion Therapeutics has a twelve month low of $1.35 and a twelve month high of $3.81.

Institutional Investors Weigh In On Esperion Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Eaton Financial Holdings Company LLC bought a new position in Esperion Therapeutics during the 3rd quarter valued at approximately $73,000. Barclays PLC raised its stake in Esperion Therapeutics by 99.6% during the third quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock valued at $510,000 after buying an additional 154,509 shares during the last quarter. Geode Capital Management LLC raised its stake in Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in Esperion Therapeutics during the third quarter valued at $606,000. Finally, Anson Funds Management LP bought a new stake in shares of Esperion Therapeutics in the 3rd quarter worth $540,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.